Stereocontrolled preparation of a nonpeptidal (-)-spirobicyclic NK-1 receptor antagonist

被引：36
|
作者：
Maligres, PE
Waters, MM
Lee, J
Reamer, RA
Askin, D
Ashwood, MS
Cameron, M
机构：
[1] Merck & Co Inc, Merck Res Labs, Dept Proc Res, Rahway, NJ 07065 USA
[2] Merck & Co Inc, Merck Sharp & Dohme Res Labs, Dept Proc Res, Hoddesdon EN11 9BU, Herts, England
来源：
JOURNAL OF ORGANIC CHEMISTRY | 2002年 / 67卷 / 04期
关键词：
D O I：
10.1021/jo0157472
中图分类号：
O62 [有机化学];
学科分类号：
070303 ; 081704 ;
摘要：
The synthesis of a spirobicyclic NK-1 receptor (Substance-P) antagonist I antipode is described. Retrosynthetic analysis reveals an allylic halide A bearing the cyclopropoxy-substituted aryl group and a 2-phenyl-3-piperidone B. The stereochemistry in the spirobicyclic system bearing three chiral centers is initially set via a highly diastereoselective zinc-mediated coupling of the allylic bromide 23 to the optically active ketopiperidine 3. The remaining benzylic asymmetric center is set by a diastereoselective hydroboration followed by cyclization to the spirobicyclic system.
引用
收藏
页码：1093 / 1101
页数：9
相关论文
共 50 条
  • [41] Sequential interactions of substance P with the NK-1 receptor
    Wu, M
    Boyd, N
    FASEB JOURNAL, 2000, 14 (08) : A1381 - A1381
  • [42] Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron
    Adams, Laurel M.
    Johnson, Brendan
    Zhang, Ke
    Yue, Lin
    Kirby, Lyndon C.
    Lebowitz, Peter
    Stoltz, Randall
    SUPPORTIVE CARE IN CANCER, 2009, 17 (09) : 1187 - 1193
  • [43] Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone
    Johnson, Brendan
    Adams, Laurel
    Lu, Emily
    Zhang, Ke
    Lebowitz, Peter
    Lates, Christian
    Blum, Robert
    SUPPORTIVE CARE IN CANCER, 2009, 17 (09) : 1177 - 1185
  • [44] Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron
    Laurel M. Adams
    Brendan Johnson
    Ke Zhang
    Lin Yue
    Lyndon C. Kirby
    Peter Lebowitz
    Randall Stoltz
    Supportive Care in Cancer, 2009, 17 : 1187 - 1193
  • [45] Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone
    Brendan Johnson
    Laurel Adams
    Emily Lu
    Ke Zhang
    Peter Lebowitz
    Christian Lates
    Robert Blum
    Supportive Care in Cancer, 2009, 17 : 1177 - 1185
  • [46] Effect of MDL 105,212, a nonpeptide NK-1/NK-2 receptor antagonist in an allergic guinea pig model
    Kudlacz, EM
    Knippenberg, RW
    Logan, DE
    Burkholder, TP
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1996, 279 (02) : 732 - 739
  • [47] THE NK-1 RECEPTOR ANTAGONIST, CP-96,345, INHIBITS THE ADHESION OF NEUTROPHILS AND EOSINOPHILS IN RAT TRACHEA
    BALUK, P
    BERTRAND, C
    GEPPETTI, P
    MCDONALD, DM
    NADEL, JA
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1993, 147 (04): : A475 - A475
  • [48] Effects of NK-1 receptor antagonist AV608 on emotional circuitry and affect in female IBS patients
    Bueller, Joshua A.
    Tillisch, Kristen
    Nalibroff, Bruce D.
    Suyenobu, Brandall Y.
    Smith, Suzanne R.
    Bolus, Roger E.
    Mayer, Emeran A.
    GASTROENTEROLOGY, 2008, 134 (04) : A276 - A276
  • [49] CIGARETTE SMOKE-INDUCED INCREASE IN AIRWAY VASCULAR-PERMEABILITY IS PREVENTED BY NK-1 RECEPTOR ANTAGONIST
    NADEL, JA
    BERTRAND, C
    DESAI, MC
    SNIDER, RM
    PIEDIMONTE, G
    FASEB JOURNAL, 1992, 6 (04) : A1278 - A1278
  • [50] Impact of casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics of the CYP3A substrates midazolam and nifedipine
    Johnson, Brendan
    Wessels, David
    Milleri, Stefano
    Krum, Henry
    Adams, Laurel
    Fiore, Monica
    Fernandes, Sofia
    Zamuner, Stefano
    Fina, Paola
    Motta, Paola
    Pinna, Alessandro
    Peroni, Michela
    CANCER RESEARCH, 2009, 69
12345